A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Amgen
844 participants
Feb 25, 2025
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dazodalibep will be given intravenously (IV).
Locations(174)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06747949